OCUL Form 144: Insider sale notice for vested shares

Ocular Therapeutix (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on 02/22/2026.

Rhea-AI Filing Summary

Ocular Therapeutix (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on 02/22/2026.

The filing names Pravin Dugel and lists prior sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61.

Insights

Securities Lawyer

Form 144 notices a proposed resale of vested restricted shares under a registered plan.

Form 144 is a statutory notice of an intended sale under Rule 144; this filing identifies proposed sales of common stock on 02/22/2026 tied to restricted stock vesting under a registered plan.

Cash‑flow treatment and placement method are not stated in the excerpt; subsequent trade reports or a Form 4/transaction filing would confirm execution details.

Corporate Governance Analyst

Insider disposals reported recently, with multiple past‑quarter sales disclosed.

The excerpt lists prior dispositions by Pravin Dugel: 124,882 shares on 02/12/2026 and 19,530 shares on 11/24/2025, with proceeds shown in dollars. These are explicit transaction records, not company operational metrics.

Timing and execution of the 02/22/2026 sales relate to vesting; future filings may state whether sales occurred and under what method.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does OCUL's Form 144 filed on 02/22/2026 report?

It reports proposed sales of common stock tied to restricted stock vesting under a registered plan on 02/22/2026. The filing names the insider and lists prior sales with share counts and gross proceeds.

Who is the insider listed in OCUL's Form 144?

The filing names Pravin Dugel at an address in Bedford, MA. It associates him with prior sales of common shares reported on 02/12/2026 and 11/24/2025.

How many shares did Pravin Dugel sell recently according to the filing?

The excerpt shows sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61. These are reported gross proceeds.

Does the Form 144 confirm the 02/22/2026 sale executed?

No. Form 144 is a notice of proposed sale tied to vesting on 02/22/2026. Execution and method of sale are not confirmed in this excerpt and would appear in later trade‑reporting filings if sold.

Are proceeds from the proposed sales paid to the company (OCUL)?

The excerpt does not state proceeds treatment. Listed prior sales show gross proceeds to the selling person; the Form 144 itself does not indicate company receipt of proceeds in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001700917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	15 Crosby Drive Bedford MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	PRAVIN DUGEL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20056	166085.74	217691779	02/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/22/2026	Restricted stock vesting under a registered plan	Issuer			20056	02/22/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PRAVIN DUGEL 15 Crosby Drive Bedford MA 01730	Common	02/12/2026	124882	1128583.61
PRAVIN DUGEL 15 Crosby Drive Bedford MA 01730	Common	11/24/2025	19530	235082.61

144: Remarks and Signature

Remarks
Date of Notice	02/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Pravin Dugel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)